Status:
UNKNOWN
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Lead Sponsor:
Kartos Therapeutics, Inc.
Conditions:
Diffuse Large B Cell Lymphoma
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia...
Eligibility Criteria
Inclusion
- Cohort 1: Confirmed diagnosis of TP53wt DLBCL (WHO); R/R DLBCL after at least 2 prior lines of treatment or 1 prior for patients who are ineligible for stem cell transplant
- Cohort 2: Confirmed diagnosis of TP53wt CLL (iwCLL); R/R CLL after at least 1 prior line of treatment
- ECOG 0 to 2
- Adequate hematologic, hepatic, and renal functions.
Exclusion
- Prior treatment with any MDM2 inhibitor
- Prior treatment with any BTK inhibitor
Key Trial Info
Start Date :
February 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT04502394
Start Date
February 23 2021
End Date
March 1 2024
Last Update
August 4 2022
Active Locations (45)
Enter a location and click search to find clinical trials sorted by distance.
1
Goshen Center for Cancer Care
Goshen, Indiana, United States, 46526
2
University of Cincinnati
Cincinnati, Ohio, United States, 45221
3
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
4
UT Southwestern Medical Center
Dallas, Texas, United States, 75390